| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
20,889 |
18,432 |
$4.79M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
20,007 |
18,318 |
$4.25M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
5,536 |
5,154 |
$3.61M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,687 |
7,730 |
$2.66M |
| G0378 |
Hospital observation service, per hour |
7,876 |
5,336 |
$1.36M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
44,168 |
13,545 |
$1.20M |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,972 |
4,483 |
$636K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,417 |
1,315 |
$546K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
2,645 |
2,541 |
$543K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,421 |
1,326 |
$477K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,443 |
1,330 |
$448K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,272 |
4,051 |
$388K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,519 |
1,452 |
$313K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
23,189 |
8,292 |
$261K |
| 71046 |
Radiologic examination, chest; 2 views |
8,323 |
7,828 |
$238K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
823 |
772 |
$226K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
336 |
296 |
$214K |
| 72100 |
|
2,856 |
2,759 |
$201K |
| 76830 |
Ultrasound, transvaginal |
1,528 |
1,484 |
$183K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
3,652 |
1,403 |
$174K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
337 |
291 |
$153K |
| 73564 |
|
1,888 |
1,079 |
$137K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
7,709 |
3,618 |
$133K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,412 |
2,222 |
$127K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
815 |
777 |
$125K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
469 |
447 |
$123K |
| 73110 |
|
2,488 |
2,111 |
$115K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
1,369 |
1,334 |
$112K |
| 72040 |
|
1,437 |
1,383 |
$110K |
| 73610 |
|
2,491 |
2,223 |
$105K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,947 |
2,869 |
$102K |
| 73030 |
|
3,049 |
2,642 |
$101K |
| 80053 |
Comprehensive metabolic panel |
28,264 |
23,191 |
$101K |
| 59025 |
Fetal non-stress test |
1,186 |
863 |
$99K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
6,422 |
2,531 |
$95K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
246 |
236 |
$94K |
| 73562 |
|
3,007 |
2,529 |
$88K |
| 73630 |
|
2,939 |
2,569 |
$87K |
| 73130 |
|
2,575 |
2,154 |
$80K |
| 97161 |
|
4,206 |
3,999 |
$78K |
| 94726 |
|
205 |
200 |
$77K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
480 |
455 |
$74K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
914 |
865 |
$73K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
441 |
409 |
$72K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
1,997 |
1,882 |
$65K |
| 76536 |
|
762 |
742 |
$60K |
| 73502 |
|
1,748 |
1,627 |
$59K |
| 97597 |
|
834 |
282 |
$58K |
| 74018 |
|
1,538 |
1,427 |
$55K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
67 |
63 |
$52K |
| 77080 |
|
979 |
947 |
$52K |
| 71250 |
|
519 |
499 |
$48K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
13,631 |
11,970 |
$44K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
7,495 |
6,471 |
$38K |
| 97535 |
Self-care/home management training, each 15 minutes |
3,573 |
2,196 |
$37K |
| 76642 |
|
531 |
512 |
$36K |
| 72072 |
|
516 |
497 |
$34K |
| 93971 |
|
1,108 |
1,028 |
$34K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,685 |
1,576 |
$34K |
| 76770 |
|
411 |
393 |
$28K |
| 97162 |
|
1,698 |
1,573 |
$26K |
| 95811 |
|
39 |
36 |
$25K |
| 76641 |
|
177 |
158 |
$23K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
5,362 |
2,994 |
$22K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
2,953 |
2,784 |
$21K |
| 73221 |
|
127 |
114 |
$21K |
| 72141 |
|
132 |
126 |
$21K |
| J7050 |
Infusion, normal saline solution, 250 cc |
4,968 |
2,406 |
$18K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
9,559 |
8,258 |
$16K |
| 71045 |
Radiologic examination, chest; single view |
8,109 |
7,352 |
$16K |
| 97165 |
|
658 |
632 |
$15K |
| 73080 |
|
418 |
372 |
$13K |
| 70486 |
|
199 |
190 |
$13K |
| 93017 |
|
252 |
239 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,151 |
2,888 |
$11K |
| 12001 |
|
93 |
92 |
$11K |
| 87641 |
|
614 |
587 |
$11K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
13,520 |
11,710 |
$8K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
1,770 |
1,715 |
$7K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,498 |
1,658 |
$7K |
| 76937 |
|
59 |
51 |
$7K |
| 77336 |
|
47 |
24 |
$6K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
444 |
233 |
$6K |
| 73140 |
|
215 |
196 |
$6K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,162 |
2,832 |
$6K |
| 99460 |
|
82 |
81 |
$5K |
| 87186 |
|
1,450 |
1,315 |
$5K |
| 73090 |
|
206 |
179 |
$5K |
| 97116 |
|
1,328 |
642 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
236 |
233 |
$5K |
| 97750 |
|
349 |
310 |
$5K |
| 99215 |
Prolong outpt/office vis |
177 |
162 |
$5K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
330 |
181 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,203 |
4,512 |
$4K |
| 97166 |
|
70 |
66 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
100 |
62 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
57 |
53 |
$4K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
622 |
577 |
$4K |
| 97032 |
|
1,555 |
743 |
$4K |
| J3490 |
Unclassified drugs |
3,701 |
2,306 |
$4K |
| 87040 |
|
1,974 |
1,796 |
$4K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
33,053 |
26,638 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,587 |
1,376 |
$4K |
| G0379 |
Direct admission of patient for hospital observation care |
1,636 |
1,188 |
$4K |
| 72110 |
|
42 |
40 |
$4K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
9,667 |
8,142 |
$4K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
944 |
673 |
$3K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
51 |
51 |
$3K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,669 |
5,053 |
$3K |
| 94060 |
|
187 |
184 |
$3K |
| 93880 |
|
41 |
37 |
$3K |
| 90715 |
|
740 |
700 |
$3K |
| 73590 |
|
110 |
95 |
$3K |
| 70496 |
|
14 |
14 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,333 |
1,649 |
$2K |
| 70498 |
|
42 |
40 |
$2K |
| 87631 |
|
688 |
657 |
$2K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
216 |
123 |
$2K |
| 72131 |
|
26 |
24 |
$2K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
4,116 |
3,012 |
$2K |
| 87077 |
|
1,450 |
1,312 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,754 |
4,873 |
$2K |
| 76801 |
|
66 |
59 |
$2K |
| 83880 |
|
1,997 |
1,809 |
$2K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
151 |
122 |
$1K |
| 87088 |
|
5,249 |
4,777 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
37,532 |
28,543 |
$1K |
| J1815 |
Injection, insulin, per 5 units |
18 |
12 |
$1K |
| 73700 |
|
14 |
13 |
$1K |
| 80329 |
|
2,117 |
1,652 |
$1K |
| 95812 |
|
14 |
13 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
276 |
236 |
$1K |
| 97035 |
|
422 |
195 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,163 |
3,630 |
$1K |
| 74019 |
|
39 |
39 |
$1K |
| 84484 |
|
7,727 |
6,610 |
$1K |
| 77066 |
Tomosynthesis, mammo |
305 |
301 |
$1K |
| 83690 |
|
8,091 |
7,202 |
$838.30 |
| 71271 |
|
12 |
12 |
$824.29 |
| J2060 |
Injection, lorazepam, 2 mg |
1,774 |
1,488 |
$774.51 |
| 83605 |
|
6,063 |
5,289 |
$767.05 |
| 81025 |
|
4,943 |
4,600 |
$746.77 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,164 |
901 |
$732.28 |
| 85610 |
|
7,201 |
6,192 |
$725.89 |
| 86141 |
|
209 |
171 |
$598.97 |
| 86140 |
|
464 |
389 |
$597.23 |
| 84703 |
|
2,576 |
2,425 |
$554.60 |
| 81001 |
|
10,620 |
9,645 |
$537.54 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
416 |
390 |
$527.67 |
| 83735 |
|
5,137 |
3,993 |
$519.76 |
| 94729 |
|
230 |
224 |
$475.20 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
504 |
472 |
$473.42 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,238 |
5,587 |
$434.67 |
| 85379 |
|
1,640 |
1,547 |
$433.94 |
| 77065 |
Tomosynthesis, mammo |
55 |
50 |
$421.92 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,032 |
6,010 |
$387.17 |
| 85730 |
|
2,109 |
1,880 |
$382.60 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,676 |
2,462 |
$365.45 |
| 84702 |
|
551 |
500 |
$324.99 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
28 |
24 |
$305.00 |
| 82803 |
|
570 |
512 |
$262.36 |
| 87070 |
|
254 |
233 |
$244.82 |
| 74022 |
|
12 |
12 |
$242.86 |
| 96376 |
|
2,689 |
2,352 |
$226.81 |
| 80061 |
Lipid panel |
300 |
284 |
$216.01 |
| A9270 |
Non-covered item or service |
2,916 |
786 |
$210.23 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
8,229 |
7,564 |
$204.67 |
| 88342 |
|
98 |
94 |
$187.21 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
244 |
224 |
$154.89 |
| 82140 |
|
31 |
27 |
$151.03 |
| 86900 |
|
1,035 |
865 |
$139.09 |
| 80320 |
|
3,997 |
3,513 |
$137.69 |
| 81003 |
|
5,186 |
4,808 |
$137.68 |
| 97803 |
|
13 |
13 |
$109.65 |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
16 |
14 |
$92.27 |
| 82962 |
|
3,984 |
2,700 |
$89.39 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,395 |
1,123 |
$87.98 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
891 |
822 |
$81.27 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,545 |
2,216 |
$80.48 |
| 86901 |
|
763 |
655 |
$70.75 |
| 82550 |
|
1,216 |
1,071 |
$65.31 |
| 82150 |
|
237 |
223 |
$58.18 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,798 |
1,568 |
$56.82 |
| 84100 |
|
1,747 |
1,192 |
$56.17 |
| J3480 |
Injection, potassium chloride, per 2 meq |
94 |
81 |
$54.09 |
| 86850 |
|
462 |
395 |
$53.23 |
| 96367 |
|
43 |
24 |
$49.42 |
| 82776 |
|
12 |
12 |
$47.80 |
| 97016 |
|
5,254 |
1,631 |
$46.56 |
| 87581 |
|
586 |
552 |
$45.75 |
| 87486 |
|
586 |
552 |
$45.75 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,079 |
981 |
$45.33 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
912 |
863 |
$25.00 |
| 84145 |
|
148 |
136 |
$17.77 |
| J1644 |
Injection, heparin sodium, per 1000 units |
296 |
135 |
$12.82 |
| J1630 |
Injection, haloperidol, up to 5 mg |
68 |
57 |
$6.31 |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
92 |
80 |
$5.00 |
| 87205 |
|
262 |
239 |
$4.01 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
351 |
318 |
$2.48 |
| 85652 |
|
472 |
370 |
$1.73 |
| S0028 |
Injection, famotidine, 20 mg |
305 |
270 |
$0.95 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
2,709 |
2,637 |
$0.36 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
150 |
125 |
$0.02 |
| 94760 |
|
1,448 |
1,078 |
$0.00 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
877 |
827 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
104 |
87 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
28 |
24 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
146 |
133 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
95 |
79 |
$0.00 |
| J1790 |
Injection, droperidol, up to 5 mg |
80 |
69 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
147 |
130 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
83 |
79 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
61 |
50 |
$0.00 |
| 88738 |
|
71 |
69 |
$0.00 |
| 97014 |
|
30 |
12 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
34 |
20 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
65 |
53 |
$0.00 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
42 |
30 |
$0.00 |
| 85027 |
|
50 |
40 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
57 |
32 |
$0.00 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
17 |
15 |
$0.00 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
15 |
13 |
$0.00 |
| J2785 |
Injection, regadenoson, 0.1 mg |
14 |
12 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
20 |
12 |
$0.00 |
| J3535 |
Drug administered through a metered dose inhaler |
13 |
12 |
$0.00 |
| 88304 |
|
12 |
12 |
$0.00 |
| G8991 |
Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
12 |
$0.00 |
| 82270 |
|
27 |
26 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
3,200 |
2,716 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
203 |
188 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
84 |
82 |
$0.00 |
| 84439 |
|
64 |
60 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
360 |
292 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
618 |
483 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
493 |
398 |
$0.00 |
| 94799 |
|
36 |
29 |
$0.00 |
| S4991 |
Nicotine patches, non-legend |
15 |
12 |
$0.00 |
| 77061 |
|
12 |
12 |
$0.00 |
| 77062 |
|
38 |
38 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
16 |
12 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
47 |
38 |
$0.00 |
| 29125 |
|
14 |
13 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
63 |
56 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
40 |
18 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
35 |
29 |
$0.00 |
| 76376 |
|
43 |
41 |
$0.00 |